Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide, Leuprolide Acetate, and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumor
NCT06169124Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2024
- Primary completion
- Feb 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in ovarian granulosa cell tumor (OGCT), sponsored by National Cancer Institute. Started Feb 2024; status: completed.
02
Drugs
darolutamide
03
Conditions
ovarian granulosa cell tumor (OGCT)
Beyond the preview
Go deeper on NCT06169124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169124.